Olectan Hct (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan medoxomil, amlodipine and hydrochlorothiazide, the active ingredients in Olectan Hct, are an angiotensin II receptor blocker, calcium channel blocker and thiazide diuretic presented as an oral tablet for oral use. It treats hypertension in adult patients. GNH USA supplies Olectan Hct as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olectan Hct, a combination antihypertensive, is indicated for the management of high blood pressure across several clinical presentations.

Hypertension (essential): reduces systolic and diastolic pressure in patients with primary hypertension. Isolated systolic hypertension: lowers elevated systolic values in older adults. Resistant hypertension: provides additional blood‑pressure control when single‑agent therapy is insufficient.

Common Side Effects: - Dizziness or light‑headedness - Headache - Peripheral edema, especially of the ankles - Flushing or warmth sensation - Increased urinary frequency - Mild electrolyte disturbances (e.g., low potassium)

Serious or Rare Side Effects: - Angioedema or severe swelling of face/lips - Marked hypotension leading to fainting - Acute kidney injury or worsening renal function - Severe electrolyte imbalance (e.g., hyponatremia, hyperkalemia) - Pancreatitis (rare) - Hepatic dysfunction (rare)

Before initiating therapy, consider the following precautions: - Monitor blood pressure regularly to assess efficacy. - Assess renal function and serum electrolytes, especially potassium and sodium. - Evaluate hepatic function in patients with liver disease. - Use caution in patients with a history of gout, as thiazides may increase uric acid. - Avoid in individuals with severe hypotension or overt heart failure. Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Olectan Hct may interact with several drug classes; awareness of major and moderate interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - Concomitant use with aliskiren in diabetic patients may increase risk of renal impairment. - Lithium therapy can lead to lithium toxicity due to reduced clearance. - Potassium‑sparing diuretics or supplements may cause dangerous hyperkalemia. - Strong CYP3A4 inhibitors (e.g., ketoconazole) can raise amlodipine levels.

Moderate Interactions (Monitor Closely): - NSAIDs may blunt antihypertensive effect and affect renal function. - ACE inhibitors or other ARBs can increase risk of renal dysfunction and hyperkalemia. - Beta‑blockers may produce additive blood‑pressure lowering. - Digoxin levels may rise when combined with amlodipine.